117 related articles for article (PubMed ID: 38882702)
1. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
[TBL] [Abstract][Full Text] [Related]
2. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.
Erickson CM; Chin NA; Rosario HL; Peterson A; Johnson SC; Clark LR
Alzheimers Dement (N Y); 2023; 9(3):e12413. PubMed ID: 37521522
[TBL] [Abstract][Full Text] [Related]
4. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Mozersky J; Sankar P; Harkins K; Hachey S; Karlawish J
JAMA Neurol; 2018 Jan; 75(1):44-50. PubMed ID: 29059270
[TBL] [Abstract][Full Text] [Related]
5. Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
Largent EA; Abera M; Harkins K; Feldman SJ; Uhlmann WR; Roberts JS; Karlawish J;
J Am Geriatr Soc; 2021 Nov; 69(11):3203-3211. PubMed ID: 34252201
[TBL] [Abstract][Full Text] [Related]
6. Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.
Grill JD; Cox CG; Harkins K; Karlawish J
Alzheimers Res Ther; 2018 Dec; 10(1):125. PubMed ID: 30579361
[TBL] [Abstract][Full Text] [Related]
7. Reasons for undergoing amyloid imaging among cognitively unimpaired older adults.
Ryan MM; Gillen DL; Grill JD
Ann Clin Transl Neurol; 2021 Aug; 8(8):1646-1655. PubMed ID: 34227249
[TBL] [Abstract][Full Text] [Related]
8. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
9. Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial.
Grill JD; Raman R; Ernstrom K; Wang S; Donohue MC; Aisen PS; Karlawish J; Henley D; Romano G; Novak G; Brashear HR; Sperling RA
Neurol Clin Pract; 2024 Apr; 14(2):e200265. PubMed ID: 38585443
[TBL] [Abstract][Full Text] [Related]
10. A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.
Erickson CM; Karlawish J; Grill JD; Harkins K; Landau SM; Rivera-Mindt MG; Okonkwo O; Petersen RC; Aisen PS; Weiner MW; Largent EA
J Prev Alzheimers Dis; 2024; 11(2):294-302. PubMed ID: 38374735
[TBL] [Abstract][Full Text] [Related]
11. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Grill JD; Zhou Y; Elashoff D; Karlawish J
Neurobiol Aging; 2016 Mar; 39():147-53. PubMed ID: 26923411
[TBL] [Abstract][Full Text] [Related]
12. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
[TBL] [Abstract][Full Text] [Related]
13. Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.
Vanderschaeghe G; Vandenberghe R; Dierickx K
J Bioeth Inq; 2019 Mar; 16(1):45-59. PubMed ID: 30868358
[TBL] [Abstract][Full Text] [Related]
14. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
Grill JD; Raman R; Ernstrom K; Sultzer DL; Burns JM; Donohue MC; Johnson KA; Aisen PS; Sperling RA; Karlawish J;
JAMA Neurol; 2020 Dec; 77(12):1504-1513. PubMed ID: 32777010
[TBL] [Abstract][Full Text] [Related]
15. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.
Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC;
JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938
[TBL] [Abstract][Full Text] [Related]
16. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
[TBL] [Abstract][Full Text] [Related]
17. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
Ritchie M; Salazar CR; Gillen DL; Grill JD
Alzheimers Dement; 2024 Apr; 20(4):2508-2515. PubMed ID: 38329007
[TBL] [Abstract][Full Text] [Related]
18. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
19. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study.
Allué JA; Pascual-Lucas M; Sarasa L; Castillo S; Sarasa M; Sáez ME; Abdel-Latif S; Rissman RA; Terencio J
Alzheimers Dement (Amst); 2023; 15(2):e12451. PubMed ID: 37274930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
